L H Opie, D Nathan, W F Lubbe. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Action PotentialsAdrenergic beta-Antagonists/therapeutic useAnimalsAnti-Arrhythmia Agents/adverse effectsAnti-Arrhythmia Agents/therapeutic useArrhythmias, Cardiac/drug therapyArrhythmias, Cardiac/metabolismArrhythmias, Cardiac/physiopathologyBucladesineCatecholamines/metabolismCatecholamines/physiologyCyclic AMP/metabolismCyclic AMP/physiologyFatty Acids, Nonesterified/bloodGlycolysisHumansHyperkalemia/complicationsLactates/bloodMembrane PotentialsMyocardial Infarction/complicationsMyocardium/metabolismPotassium/metabolismPurkinje Fibers/physiopathologyTheophyllineVentricular Fibrillation/drug therapyVentricular Fibrillation/metabolismVentricular Fibrillation/physiopathology
Substances: See more » Adrenergic beta-AntagonistsAnti-Arrhythmia AgentsCatecholaminesFatty Acids, NonesterifiedLactatesBucladesineTheophyllineCyclic AMPPotassium
Year: 1979 PMID: 31786 DOI: 10.1016/0002-9149(79)90055-9
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778